In current drug discovery pipeline, in vitro biochemical and cell-based screening assays have been widely used before the validation tests in in vivo animal models.Nevertheless, the gap between two platforms sometimes impairs the discovery progress, especially for the diseases with complicated mechanisms.In order to minimize such gap in the CNS disease area, we have developed several Drosophila models as supplementary approaches in parallel to the in vitro assays.These CNS fly models preserve behavioral deficits and pathological hallmarks similar to those observed in human patients, yet are low in running cost and are suitable for high-throughput screening expansions.The fly Alzheimers disease (AD) model was generated through targeted pan-neuronal expression of a transgene encoding a secretive form of human Aβ42 peptides in the Drosophila brain.Such expression leads to neurodegeneration with accumulation of Aβ42 and fibril deposits in the brain area, which may lead to shortened life span.In addition, AD flies also display severe age-dependent memory loss, highly mimicking dementia syndrome in AD patients.PC-controlled massive screening devices were utilize in the fly memory (T-maze) system, enabling screening of hundreds of compounds per day in scale for industrial needs.Fly model for NF1, Noonan syndrome were developed for drug screening service, along with other CNS disease models such as Parkinsons disease (PD), schizophrenia, and autism that have also been planned for the pipelines in CNS drug discovery.